Renovaro Stock News

BETHESDA, MD / ACCESS Newswire / September 11, 2025 / Lunai Bioworks Inc.'s (NASDAQ:RENB) wholly-owned subsidiary BioSymetrics Inc. today announced the award of a prestigious Small Business Technology Transfer (STTR) grant from the National Institutes of Health (NIH). The funding, awarded jointly to BioSymetrics and Brigham and Women's Hospital, will support the development of a novel platform ...

Proprietary safety intelligence creates dual value: faster therapeutic development and biodefense. LOS ANGELES, CALIFORNIA / ACCESS Newswire / September 9, 2025 / Lunai Bioworks Inc. (NASDAQ:RENB), an AI-powered drug discovery and biodefense company, today announced the launch of a transformer-based platform that embeds biological risk intelligence directly into large language model (LLM) pipel...

Company remains committed to Europe with a streamlined, growth-focused approach. LOS ANGELES, CALIFORNIA / ACCESS Newswire / September 8, 2025 / Lunai Bioworks Inc. (Nasdaq:RENB), an AI-powered drug discovery and biodefense company, today reaffirmed its long-term commitment to European markets and partnerships while announcing the elimination of its legacy subsidiary, Gedi Cube B.V.

Collaboration aims to apply Lunai Bioworks Inc. biomedical AI platform to accelerate countermeasure development for chemical agents like sarin and other biothreats LOS ANGELES, CALIFORNIA / ACCESS Newswire / September 4, 2025 / Lunai Bioworks Inc. DBA Renovaro Inc. (NASDAQ:RENB), Lunai Bioworks Inc. is an AI-powered tech bio company pioneering safe and responsible generative biology. With propr...

LOS ANGELES, CALIFORNIA / ACCESS Newswire / August 27, 2025 / Renovaro Inc. (NASDAQ:RENB) today announced that it will change its corporate name to Lunai Bioworks, Inc. to better reflect its strategic direction and growing expertise in AI-powered biodefense, drug discovery and advanced diagnostics. The new name underscores the Company's commitment to harnessing advanced computational biology an...

LOS ANGELES, CALIFORNIA / ACCESS Newswire / August 8, 2025 / Renovaro Inc. (NASDAQ:RENB) was referenced in a recent RealClearDefense article titled "AI Can Be Used to Develop Biological and Chemical Weapons", which examines the complex challenges posed by artificial intelligence in the context of global security and biodefense. The full article can be accessed at: https://www.realcleardefense.c...

Strategic IP expansion protects federated learning technology driving pharma partnerships, biosecurity initiatives, and precision medicine growth LOS ANGELES, CALIFORNIA / ACCESS Newswire / July 28, 2025 / Renovaro (NASDAQ:RENB), a precision-medicine technology company, today announced multiple U.S. patent allowances that significantly strengthen its competitive position in biomedical artificia...

Landmark preclinical data validate Renovaro's platform representing a step forward in the fight against pancreatic and solid tumors LOS ANGELES, CALIFORNIA / ACCESS Newswire / July 17, 2025 / Renovaro Biosciences (NASDAQ:RENB), an oncology and neurology focused TechBio company, today announced the publication of a peer-reviewed study in Vaccines, a leading journal in the field of immunology. Th...